First dosing at Ambade Eye Hospital in Nagpur, India, marks a key milestone in the clinical development of Treyegen™
PLANO, Texas — November 2, 2026
“Dosing the first patient in EMERALD represents an important milestone in Okogen’s development of Treyegen,” said Joshua Moriarty, Chief Executive Officer of Okogen. “We built Treyegen around a clear goal: to change how acute infectious conjunctivitis is treated. Physicians need a therapy designed for the uncertainty they face at the first visit, when the cause of infection is often unknown. EMERALD is our opportunity to test that approach and generate the evidence needed to move it forward.”
Acute infectious conjunctivitis can involve viral or bacterial pathogens often with overlapping clinical presentations. Physicians frequently must make treatment decisions before laboratory confirmation is available. Treyegen is being developed to address this challenge by bringing complementary antiviral, antibacterial and symptom-relieving mechanisms into a single investigational ophthalmic therapy. Currently, there are no FDA-approved antiviral therapies specifically indicated for adenoviral conjunctivitis, one of the most common causes of infectious conjunctivitis.
